Blood Pressure and Progression of Diabetic Kidney Disease

血压与糖尿病肾病的进展

基本信息

批准号：
8765550
负责人：
Emily Bartlett Schroeder
金额：
$ 17.47万
依托单位：
KAISER FOUNDATION RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-01 至 2019-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8765550
关键词：
Accounting Address Adherence Adrenergic beta-Antagonists Adverse effects Algorithms Angiotensin II Receptor Angiotensin-Converting Enzyme Inhibitors Antihypertensive Agents Area Biometry Blood Pressure Calcium Channel Blockers Cardiovascular Diseases Caring Chronic Kidney Failure Clinical Clinical Pharmacists Clinical Treatment Clinical Trials Colorado Databases Development Development Plans Diabetes Mellitus Diabetic Nephropathy Dialysis procedure Diuretics Doctor of Philosophy Effectiveness End stage renal failure Endocrinologist Endocrinology Environment Epidemiology Fostering Funding Glomerular Filtration Rate Goals Health Health Care Costs Health Maintenance Organizations Home Blood Pressure Monitoring Hypotension Individual Institutes Intervention K-Series Research Career Programs Kidney Transplantation Leadership Learning Mentored Patient-Oriented Research Career Development Award Mentors Mentorship Methods Morbidity - disease rate National Institute of Diabetes and Digestive and Kidney Diseases Nephrology Outcome Pharmaceutical Preparations Process Measure Publications Quality of life Randomized Clinical Trials Recording of previous events Relative (related person)Renin-Angiotensin-Aldosterone System Research Research Activity Research Personnel Research Training Safety Selection for Treatments Site Staging Training Training Activity Translational Research Treatment Protocols United States base blood pressure regulation career career development comparative effectiveness cost design effectiveness research experience group intervention hypertension treatment improved innovation medication compliance mortality motivational enhancement therapy non-diabetic prevent primary outcome public health relevance secondary outcome treatment adherence treatment as usual

Accounting Address Adherence Adrenergic beta-Antagonists Adverse effects Algorithms Angiotensin II Receptor Angiotensin-Converting Enzyme Inhibitors Antihypertensive Agents Area Biometry Blood Pressure Calcium Channel Blockers Cardiovascular Diseases Caring Chronic Kidney Failure Clinical Clinical Pharmacists Clinical Treatment Clinical Trials Colorado Databases Development Development Plans Diabetes Mellitus Diabetic Nephropathy Dialysis procedure Diuretics Doctor of Philosophy Effectiveness End stage renal failure Endocrinologist Endocrinology Environment Epidemiology Fostering Funding Glomerular Filtration Rate Goals Health Health Care Costs Health Maintenance Organizations Home Blood Pressure Monitoring Hypotension Individual Institutes Intervention K-Series Research Career Programs Kidney Transplantation Leadership Learning Mentored Patient-Oriented Research Career Development Award Mentors Mentorship Methods Morbidity - disease rate National Institute of Diabetes and Digestive and Kidney Diseases Nephrology Outcome Pharmaceutical Preparations Process Measure Publications Quality of life Randomized Clinical Trials Recording of previous events Relative (related person)Renin-Angiotensin-Aldosterone System Research Research Activity Research Personnel Research Training Safety Selection for Treatments Site Staging Training Training Activity Translational Research Treatment Protocols United States base blood pressure regulation career career development comparative effectiveness cost design effectiveness research experience group intervention hypertension treatment improved innovation medication compliance mortality motivational enhancement therapy non-diabetic prevent primary outcome public health relevance secondary outcome treatment adherence treatment as usual

展开

项目摘要

DESCRIPTION (provided by applicant): This is a submission for an NIDDK K23 Mentored Patient-Oriented Research Career Development Award (PA- 11-194). Dr. Emily Schroeder's overarching career goal is to be a leader in the conduct of research that improves the lives of individuals with diabetes. Her research explores the treatment of blood pressure on the progression of diabetic kidney disease. Candidate: Dr. Schroeder is an Investigator at the Institute for Health Research at Kaiser Permanente Colorado and an Endocrinologist at Kaiser Permanente Colorado. She has prior training in epidemiology and endocrinology, and an early track record of publications and research funding. Training: The proposed K23 career development plan builds upon Dr. Schroeder's prior experience in epidemiology and endocrinology to focus on two areas that require additional training: 1) Methods for observational comparative effectiveness research, and 2) Conduct of pragmatic clinical trials. Accordingly, Dr. Schroeder proposes intensive topical mentorship, focused coursework, seminars, and contextual learning through the proposed research. Mentors/Environment: Dr. Schroeder and her primary mentor, Dr. John Steiner, have assembled a strong mentorship team who will guide Dr. Schroeder through the proposed training and research activities. This mentorship team includes expertise in nephrology, biostatistics, pragmatic clinical trials, and translational research. Her research will take place within the Institute for Health Research, which has a long history of leadership in national research networks. This research uses a large, innovative, and newly created database of over one million individuals with diabetes across 11 U.S. health maintenance organizations. Research: Diabetic kidney disease is a major cause of morbidity and mortality in the United States. Aim 1 is a study of the comparative effectiveness and safety of second-line blood pressure agents for the treatment of diabetic kidney disease to determine if there is a class effect independent of level of achieved blood pressure control. Aim 2 extends the findings of Aim 1 to examine the effect of ongoing treatment with different second- line blood pressure agents, as opposed to the effect of initial treatment assignment determined in Aim 1. Aim 3 is a pilot pragmatic clinical trial to improve blood pressure control among individuals with both diabetes and stage 3 chronic kidney disease. Summary: Conduct of this mentored research and training proposal, "Blood Pressure and Progression of Diabetic Kidney Disease," will facilitate Dr. Schroeder's development into a nationally-recognized independent investigator and leader conducting research to improve the lives of individuals with diabetes.

描述（由申请人提供）：这是NIDDK K23指导的以患者为导向的研究职业发展奖（PA-11-194）的提交。艾米丽·施罗德（Emily Schroeder）博士的总体职业目标是成为改善糖尿病患者生活的研究的领导者。她的研究探讨了血压对糖尿病肾脏疾病进展的治疗。候选人：Schroeder博士是Kaiser Permanente Colorado的健康研究所的研究人员，也是Kaiser Permanente Colorado的内分泌学家。她先前接受过流行病学和内分泌学的培训，以及出版物和研究资金的早期记录。培训：拟议的K23职业发展计划基于施罗德博士在流行病学和内分泌学领域的先前经验，专注于需要额外培训的两个领域：1）观察性比较有效性研究的方法，以及2）进行务实的临床试验。因此，Schroeder博士通过拟议的研究提出了密集的主题指导，专注的课程，研讨会和上下文学习。导师/环境：Schroeder博士及其主要导师John Steiner博士组建了一个强大的指导团队，该团队将指导Schroeder博士通过拟议的培训和研究活动。该指导团队包括肾脏学，生物统计学，实用临床试验和转化研究方面的专业知识。她的研究将在健康研究所进行，该研究所在国家研究网络中具有悠久的领导历史。这项研究使用了一个大型，创新且新创建的数据库，其中包括11个美国健康维护组织中有超过一百万患有糖尿病的人。研究：糖尿病性肾脏疾病是美国发病率和死亡率的主要原因。 AIM 1是对二线血压剂在治疗糖尿病肾脏疾病治疗的比较有效性和安全性的研究，以确定与达到血压控制水平无关的类效应。 AIM 2扩展了AIM 1的发现，以检查与AIM 1中确定的初始治疗分配的持续治疗的持续治疗。摘要：这项受过指导的研究和培训建议的行为，“糖尿病肾脏疾病的血压和进展”，将促进施罗德博士的发展，成为全国认可的独立研究者和领导者，从而改善糖尿病患者的生活。